TCR2 is strategically positioned at the forefront of biotechnology, leveraging its profound expertise in T cell engineering to revolutionize cancer treatment. Founded in 2015 by Dr. Patrick Baeuerle and MPM Capital, the company is dedicated to pioneering innovative solutions in the pharmaceutical industry.
Operating from the renowned scientific hub of Kendall Square, Cambridge, Massachusetts, TCR2 has developed a unique, first-in-class approach to T cell cancer therapy. This cutting-edge method distinguishes itself from traditional CAR-T cells and related TCR technologies, underscoring the company's commitment to advancing life sciences.
Recently, TCR2 captured the interest of investors with an acquisition investment from Adapt Ventures on 01 March 2023. The company's ongoing collaboration with leading academic laboratories worldwide further amplifies its potential for robust growth in the Biotechnology and Health Care sectors.
